City Therapeutics, Inc. (NASDAQ:CTY) Stock Has Average Price Target of $37.33

City Therapeutics, Inc. (NASDAQ:CTY) has received an average recommendation of “Moderate Buy” from the four brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $37.33.

A number of analysts have recently commented on the company. Stifel Nicolaus assumed coverage on City Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $34.00 price objective on the stock. Wall Street Zen raised City Therapeutics to a “hold” rating in a research note on Saturday, October 24th. Zacks Research assumed coverage on City Therapeutics in a report on Wednesday. They set a “hold” rating on the stock. Jefferies Financial Group assumed coverage on shares of City Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Oppenheimer began coverage on shares of City Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $46.00 price target for the company.

City Therapeutics Stock Up 11.6%

CTY opened at $18.98 on Friday. City Therapeutics has a twelve month low of $15.81 and a twelve month high of $23.88.

Insider Transactions at City Therapeutics

In other City Therapeutics news, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the firm’s stock in a transaction on Monday, October 19th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the transaction, the insider owned 13,692,507 shares of the company’s stock, valued at $246,465,126. The trade was a 1.26% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Nelsen acquired 170,000 shares of the stock in a transaction that occurred on Monday, October 19th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the transaction, the director directly owned 13,692,507 shares of the company’s stock, valued at $246,465,126. This represents a 1.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About City Therapeutics

City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.